Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer.
Saved in:
| Title: | Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer. |
|---|---|
| Authors: | Valenza C; Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Partridge AH; Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Regan MM; Harvard Medical School, Boston, MA, USA; Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: mregan@jimmy.harvard.edu. |
| Source: | Breast (Edinburgh, Scotland) [Breast] 2026 Feb; Vol. 85, pp. 104696. Date of Electronic Publication: 2026 Jan 12. |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
